La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
ProPhase Labs Crescita futura
Future criteri di controllo 5/6
ProPhase Labs is forecast to grow earnings and revenue by 110.2% and 74% per annum respectively while EPS is expected to grow by 133.7% per annum.
Informazioni chiave
110.2%
Tasso di crescita degli utili
133.7%
Tasso di crescita dell'EPS
| Pharmaceuticals crescita degli utili | 23.6% |
| Tasso di crescita dei ricavi | 74.0% |
| Rendimento futuro del capitale proprio | n/a |
| Copertura analitica | Low |
| Ultimo aggiornamento | 13 May 2024 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Market Cool On ProPhase Labs, Inc.'s (NASDAQ:PRPH) Revenues Pushing Shares 26% Lower
Jul 03
Does This Valuation Of ProPhase Labs, Inc. (NASDAQ:PRPH) Imply Investors Are Overpaying?
Mar 04ProPhase Labs, Inc.'s (NASDAQ:PRPH) Business And Shares Still Trailing The Industry
Jan 09ProPhase Labs, Inc. (NASDAQ:PRPH) Shares Could Be 28% Above Their Intrinsic Value Estimate
Sep 21Here's Why ProPhase Labs (NASDAQ:PRPH) Can Afford Some Debt
Aug 11We Ran A Stock Scan For Earnings Growth And ProPhase Labs (NASDAQ:PRPH) Passed With Ease
Apr 07ProPhase Labs (NASDAQ:PRPH) Seems To Use Debt Quite Sensibly
Jan 24ProPhase Labs: Small Cap Stock With Strong Fundamentals And Growth Potential
Oct 13ProPhase Labs Q2 2022 Earnings Preview
Aug 10We Think ProPhase Labs (NASDAQ:PRPH) Can Stay On Top Of Its Debt
Jul 26ProPhase Labs to license two investigational cancer compounds from Global BioLife
Jul 21ProPhase Labs: A Stellar Quarter And Another Special Dividend
May 16ProPhase Labs (NASDAQ:PRPH) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Apr 08ProPhase Labs (NASDAQ:PRPH) Is Using Debt Safely
Mar 23Rock star Growth Puts ProPhase Labs (NASDAQ:PRPH) In A Position To Use Debt
Nov 30As Employer Vaccine Mandates Fail, Prophase Labs Could Benefit
Oct 20Calculating The Fair Value Of ProPhase Labs, Inc. (NASDAQ:PRPH)
Jul 22ProPhase Labs Is A Potential Pure Play On Worries About The Delta And Delta Plus Covid-19 Variants
Jun 28Here's Why Shareholders May Consider Paying ProPhase Labs, Inc.'s (NASDAQ:PRPH) CEO A Little More
May 14ProPhase Labs partners with Dutchess County New York to provide COVID-19 testing
May 06A Look At The Intrinsic Value Of ProPhase Labs, Inc. (NASDAQ:PRPH)
Apr 12Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Guadagni | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2026 | 197 | 32 | N/A | N/A | 1 |
| 12/31/2025 | 138 | 12 | N/A | N/A | 1 |
| 12/31/2024 | 47 | -17 | N/A | N/A | 3 |
| 6/30/2024 | 18 | -26 | -18 | -15 | N/A |
| 3/31/2024 | 29 | -24 | -21 | -17 | N/A |
| 12/31/2023 | 44 | -17 | -15 | -11 | N/A |
| 9/30/2023 | 63 | -10 | -14 | -10 | N/A |
| 6/30/2023 | 79 | -4 | -6 | -3 | N/A |
| 3/31/2023 | 94 | 7 | 5 | 9 | N/A |
| 12/31/2022 | 123 | 18 | 25 | 29 | N/A |
| 9/30/2022 | 146 | 31 | 21 | 23 | N/A |
| 6/30/2022 | 131 | 27 | 13 | 15 | N/A |
| 3/31/2022 | 111 | 18 | 13 | 15 | N/A |
| 12/31/2021 | 79 | 6 | -18 | -14 | N/A |
| 9/30/2021 | 39 | -5 | -21 | -16 | N/A |
| 6/30/2021 | 33 | -2 | -16 | -11 | N/A |
| 3/31/2021 | 28 | 0 | -16 | -11 | N/A |
| 12/31/2020 | 15 | -2 | -4 | -3 | N/A |
| 9/30/2020 | 12 | -2 | 3 | 4 | N/A |
| 6/30/2020 | 11 | -2 | 3 | 3 | N/A |
| 3/31/2020 | 9 | -3 | -2 | -2 | N/A |
| 12/31/2019 | 10 | -3 | -1 | -1 | N/A |
| 9/30/2019 | 11 | -3 | -1 | -1 | N/A |
| 6/30/2019 | 11 | -4 | -2 | -2 | N/A |
| 3/31/2019 | 12 | -3 | -1 | -1 | N/A |
| 12/31/2018 | 13 | -2 | -2 | -2 | N/A |
| 9/30/2018 | 13 | -1 | -3 | -3 | N/A |
| 6/30/2018 | 14 | -1 | -2 | -2 | N/A |
| 3/31/2018 | 13 | -1 | N/A | -6 | N/A |
| 12/31/2017 | 10 | -2 | N/A | -3 | N/A |
| 9/30/2017 | 6 | -3 | N/A | -1 | N/A |
| 6/30/2017 | 5 | -3 | N/A | -1 | N/A |
| 3/31/2017 | 4 | -3 | N/A | 2 | N/A |
| 12/31/2016 | 4 | -4 | N/A | 0 | N/A |
| 9/30/2016 | -6 | -3 | N/A | -2 | N/A |
| 6/30/2016 | -3 | -2 | N/A | -4 | N/A |
| 3/31/2016 | -2 | -2 | N/A | -5 | N/A |
| 12/31/2015 | 3 | -2 | N/A | -3 | N/A |
| 9/30/2015 | 21 | -3 | N/A | -4 | N/A |
| 6/30/2015 | 22 | -7 | N/A | -3 | N/A |
| 3/31/2015 | 22 | -8 | N/A | -4 | N/A |
| 12/31/2014 | 22 | -8 | N/A | -3 | N/A |
| 9/30/2014 | 23 | -7 | N/A | -1 | N/A |
| 6/30/2014 | 24 | -2 | N/A | -1 | N/A |
| 3/31/2014 | 24 | -1 | N/A | 0 | N/A |
| 12/31/2013 | 25 | 0 | N/A | 1 | N/A |
| 9/30/2013 | 25 | 0 | N/A | -2 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: PRPH is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).
Guadagni vs Mercato: PRPH is forecast to become profitable over the next 3 years, which is considered above average market growth.
Guadagni ad alta crescita: PRPH is expected to become profitable in the next 3 years.
Ricavi vs Mercato: PRPH's revenue (74% per year) is forecast to grow faster than the US market (8.8% per year).
Ricavi ad alta crescita: PRPH's revenue (74% per year) is forecast to grow faster than 20% per year.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Insufficient data to determine if PRPH's Return on Equity is forecast to be high in 3 years time